Huiling Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Huiling Zhang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dongdong Ru
Department of General Surgery, Jincheng People’s Hospital, Jincheng 048026, China
1 shared publication - Feng Zhu
Department of General Surgery, Tianjin Medical University General Hospital, Tianjin 300052, China
1 shared publication - Hui Tang
Department of Interventional and Vascular Surgery, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, 200072, People’s Republic of China
1 shared publication - Huiyuan Li
Department of General Surgery, Jincheng People’s Hospital, Jincheng 048026, China
1 shared publication - Jianfeng Li
Department of General Surgery, Jincheng People’s Hospital, Jincheng 048026, China
1 shared publication - Jiangman Zhao
Shanghai Zhangjiang Institute of Medical Innovation, Shanghai Biotecan Pharmaceuticals Co., Ltd
1 shared publication
Latest Publications
- Open Access
- 26 May 2021
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2021, 1-10
Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy
Objectives. To verify whether the concentrations and integrity index of circulating cell-free DNA (cfDNA) in serum may be clinically useful for the progression monitoring of colorectal cancer (CRC) patients. Methods. Serum samples were collected from 76 primary CRC patients who underwent surgery, including 60 with chemotherapy and 43 with follow-up. Long (247bp) and short (115bp) DNA fragments in serum were detected by real-time quantitative PCR by amplifying the ALU repeats. Ten serum traditional biomarkers levels were detected by chemiluminescence immunoassay assay. Results. The median DNA integrity index (ALU247/ALU115) of serum DNA in the preoperative group was significantly higher than those in the postchemotherapy and the follow-up groups, while cfDNA concentration (ALU115) was significantly lower in the preoperative group compared with the postchemotherapy and the follow-up groups. CEA and CA242 were significantly lower in the postoperative group than in the preoperative group. Conclusions. Serum DNA integrity index (ALU247/115) may prove to be a promising candidate biomarker for prognostic prediction of CRC who underwent chemotherapy and during short-term follow-up.
- 26 May 2021
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2021, 1-10
Open AccessPlasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy
Objectives. To verify whether the concentrations and integrity index of circulating cell-free DNA (cfDNA) in serum may be clinically useful for the progression monitoring of colorectal cancer (CRC) patients. Methods. Serum samples were collected from 76 primary CRC patients who underwent surgery, including 60 with chemotherapy and 43 with follow-up. Long (247bp) and short (115bp) DNA fragments in serum were detected by real-time quantitative PCR by amplifying the ALU repeats. Ten serum traditional biomarkers levels were detected by chemiluminescence immunoassay assay. Results. The median DNA integrity index (ALU247/ALU115) of serum DNA in the preoperative group was significantly higher than those in the postchemotherapy and the follow-up groups, while cfDNA concentration (ALU115) was significantly lower in the preoperative group compared with the postchemotherapy and the follow-up groups. CEA and CA242 were significantly lower in the postoperative group than in the preoperative group. Conclusions. Serum DNA integrity index (ALU247/115) may prove to be a promising candidate biomarker for prognostic prediction of CRC who underwent chemotherapy and during short-term follow-up.